Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.56
Percentage change -0.91	%

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: IJH VTI IWM VB XBI VXF VBK XMHQ IWO MDY

Index	RUT	P/E	17.74	EPS (ttm)	3.43	Insider Own	1.12%	Shs Outstand	123.14M	Perf Week	2.28%
Market Cap	7.50B	Forward P/E	9.05	EPS next Y	6.73	Insider Trans	-10.49%	Shs Float	121.78M	Perf Month	6.19%
Income	444.09M	PEG	0.68	EPS next Q	0.96	Inst Own	100.63%	Short Float	8.00%	Perf Quarter	25.81%
Sales	1.02B	P/S	7.39	EPS this Y	19.62%	Inst Trans	-2.42%	Short Ratio	7.14	Perf Half Y	2.79%
Book/sh	2.95	P/B	20.61	EPS next Y	32.99%	ROA	22.79%	Short Interest	9.75M	Perf Year	45.91%
Cash/sh	4.84	P/C	12.58	EPS next 5Y	26.17%	ROE	198.42%	52W Range	37.73 - 65.53	Perf YTD	27.36%
Dividend Est.	-	P/FCF	16.01	EPS past 5Y	-	ROI	23.46%	52W High	-7.08%	Beta	1.33
Dividend TTM	-	Quick Ratio	6.78	Sales past 5Y	39.83%	Gross Margin	77.30%	52W Low	61.38%	ATR (14)	1.71
Dividend Ex-Date	-	Current Ratio	7.80	EPS Y/Y TTM	63.47%	Oper. Margin	54.32%	RSI (14)	67.33	Volatility	3.36% 2.92%
Employees	350	Debt/Eq	4.22	Sales Y/Y TTM	22.44%	Profit Margin	43.74%	Recom	2.00	Target Price	66.11
Option/Short	Yes / Yes	LT Debt/Eq	4.20	EPS Q/Q	63.03%	Payout	0.00%	Rel Volume	1.12	Prev Close	61.45
Sales Surprise	4.29%	EPS Surprise	8.78%	Sales Q/Q	29.55%	Earnings	Feb 18 AMC	Avg Volume	1.36M	Price	60.89
SMA20	3.41%	SMA50	8.65%	SMA200	12.55%	Trades		Volume	1,525,343	Change	-0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50
Sep-14-20	Resumed	JP Morgan	Overweight	$28
Jul-01-20	Initiated	The Benchmark Company	Buy	$39

Show Previous Ratings

Mar-10-25 08:57AM	Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Heres Why (Insider Monkey)
Mar-07-25 02:45PM	AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More. (Barrons.com)
Mar-05-25 02:42PM	New Version of Mercks Blockbuster Cancer Drug Threatened by Patent Battle (The Wall Street Journal)
09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Feb-26-25 08:30AM	Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference (PR Newswire)
12:45PM	Loading…
Feb-24-25 12:45PM	Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Feb-20-25 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
Feb-19-25 07:10AM	Q4 2024 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ... (GuruFocus.com)
Feb-18-25 05:30PM	Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates (Zacks)
04:25PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:25PM	Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 (Investor's Business Daily)
04:16PM	Incyte Stock Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
04:01PM	HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS (PR Newswire)
09:45AM	Loading…
Feb-13-25 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Feb-12-25 06:13AM	Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-06-25 08:00AM	Halozyme Stock Climbs Back After 2024 Sneak Peek As Earnings Loom (Investor's Business Daily)
Feb-04-25 08:30AM	Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results (PR Newswire)
Feb-03-25 07:30AM	CHMP Issues Positive Opinion for Subcutaneous RYBREVANT(amivantamab) Co-Formulated with ENHANZE for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer (PR Newswire)
Jan-31-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jan-28-25 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Jan-27-25 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily)
Jan-10-25 12:45PM	Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Jan-09-25 08:52AM	Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock? (Zacks)
Jan-08-25 02:54PM	SpringWorks Therapeutics Stock Gets A RS Rating Lift (Investor's Business Daily) +5.02%
07:43AM	Halozyme Preliminary 2024 Estimated Ranges Consistent With Guidance; Raises FY25 Guidance (RTT News)
07:00AM	Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance (PR Newswire)
08:30AM	Loading…
Jan-06-25 08:30AM	Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance (PR Newswire) +5.80%
Dec-30-24 07:00AM	Halozyme Announces Takeda Received Regulatory Approval for HYQVIA 10% Subcutaneous Injection Set with ENHANZE in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia (PR Newswire)
06:45AM	Halozyme Announces argenx's VYDURA with ENHANZE was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire)
06:30AM	Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig with ENHANZE for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo (nivolumab) Indications (PR Newswire)
Dec-23-24 12:45PM	3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks)
Dec-16-24 09:55AM	How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% (Zacks)
Dec-11-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Dec-09-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
09:40AM	Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? (Zacks)
Dec-05-24 12:45PM	Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now (Zacks)
09:40AM	Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-27-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Nov-22-24 12:12PM	Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook (Benzinga) +7.22%
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why (Zacks)
09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
09:21AM	Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal (Investing.com)
08:35AM	Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions (PR Newswire)
05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive)
Nov-21-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-19-24 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) (Zacks) +5.26%
09:40AM	Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now? (Zacks)
Nov-18-24 07:00AM	Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec (PR Newswire) -6.75%
Nov-17-24 05:24PM	Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says (Bloomberg)
Nov-15-24 12:56PM	Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion (Benzinga) -15.40%
09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
05:11AM	Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid (Investing.com)
05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
03:36AM	Germanys Evotec Gets Takeover Interest From Halozyme (Bloomberg)
Nov-14-24 04:15PM	Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction (PR Newswire) -7.93%
Nov-04-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-01-24 11:42AM	Halozyme Announces Record Earnings, Guidance (FX Empire) +13.01%
03:18AM	Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Oct-31-24 05:30PM	Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:10PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Oct-24-24 06:30AM	HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE (PR Newswire)
Oct-23-24 04:30PM	Halozyme to Report Third Quarter 2024 Financial and Operating Results (PR Newswire)
Oct-17-24 01:02PM	State Street Corp's Strategic Acquisition in Halozyme Therapeutics Inc (GuruFocus.com)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Oct-14-24 09:35AM	Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options (Zacks)
Oct-07-24 12:10PM	Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again (Zacks) -9.01%
Oct-03-24 08:00AM	Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE (PR Newswire)
Sep-20-24 11:08AM	Global Cancer Rates Surge as Biotech Innovators Work on New Therapies (PR Newswire)
Sep-16-24 06:33AM	FDA approves Roches Ocrevus Zunovo with Halozyme Enhanze delivery tech (Pharmaceutical Technology)
Sep-13-24 01:30PM	Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis (PR Newswire)
Sep-12-24 08:00PM	Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With ENHANZE for Multiple Types of Cancer (PR Newswire)
Sep-10-24 06:59AM	Q1 2025 Avid Bioservices Inc Earnings Call (Thomson Reuters StreetEvents)
Sep-05-24 11:31AM	Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-24 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-28-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Aug-27-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Aug-23-24 03:03PM	Halozyme Earnings, Guidance Point to Bullish Future (FX Empire)
Aug-14-24 07:01PM	Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Aug-07-24 04:11PM	How These Two Lesser-Known Biotech Names Obliterated Sales Expectations (Investor's Business Daily)
10:39AM	Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up (Zacks)
Aug-06-24 06:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
05:50PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:45PM	Halozyme Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:19PM	Halozyme And Ligand Two Leading Biotechs Smash Quarterly Forecasts (Investor's Business Daily)
04:01PM	HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Aug-05-24 09:16AM	Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Aug-04-24 01:33PM	3 Biotech Stocks on Track for 50% Returns (or More) by 2028 (InvestorPlace)
Jul-26-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Jul-23-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:30AM	Halozyme to Report Second Quarter 2024 Financial and Operating Results (PR Newswire)
Jul-18-24 07:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-16-24 05:11PM	Big Money Eyes Halozyme for Strong Growth (FX Empire)
Jul-15-24 09:04PM	3 Biotech Stocks to Buy Now: Q3 Edition (InvestorPlace)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henderson Jeffrey William	Director	Mar 03 '25	Sale	58.69	5,000	293,458	33,611	Mar 03 08:46 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 26 '25	Sale	58.12	10,000	581,244	175,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 25 '25	Sale	58.05	10,000	580,534	185,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '25	Sale	58.28	1,697	98,902	173,756	Feb 27 06:32 PM
MICHAEL LABARRE	Officer	Feb 25 '25	Proposed Sale	58.50	21,697	1,269,274		Feb 25 04:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 23 '25	Option Exercise	0.00	4,747	0	197,863	Feb 24 05:11 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '25	Option Exercise	0.00	7,012	0	32,264	Feb 24 05:07 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '25	Option Exercise	0.00	6,688	0	35,501	Feb 24 05:04 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '25	Option Exercise	0.00	22,436	0	745,800	Feb 24 05:01 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '25	Option Exercise	0.00	31,266	0	196,729	Feb 18 06:42 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '25	Option Exercise	0.00	3,386	0	177,142	Feb 18 06:42 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '25	Option Exercise	0.00	22,205	0	32,411	Feb 18 06:41 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '25	Option Exercise	0.00	27,831	0	33,402	Feb 18 06:39 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '25	Option Exercise	0.00	1,254	0	16,734	Feb 18 06:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '25	Option Exercise	0.00	109,694	0	744,548	Feb 18 06:37 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '25	Option Exercise	0.00	13,092	0	679,836	Feb 18 06:37 PM
Henderson Jeffrey William	Director	Feb 03 '25	Sale	56.30	5,000	281,517	38,611	Feb 04 06:07 PM
JEFFREY HENDERSON	Director	Feb 03 '25	Proposed Sale	56.64	15,000	849,600		Feb 03 04:21 PM
Henderson Jeffrey William	Director	Jan 06 '25	Sale	50.01	10,000	500,060	43,611	Jan 07 04:14 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '25	Option Exercise	0.00	7,611	0	19,291	Jan 06 05:12 PM
JEFFREY HENDERSON	Director	Jan 06 '25	Proposed Sale	47.74	10,000	477,400		Jan 06 04:26 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Option Exercise	19.98	10,000	199,800	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Option Exercise	18.15	10,000	181,455	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Sale	53.75	10,000	537,469	173,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Sale	53.26	10,000	532,590	173,756	Oct 16 06:53 PM
MICHAEL LABARRE	Officer	Oct 16 '24	Proposed Sale	53.26	10,000	532,592		Oct 16 04:14 PM
MICHAEL LABARRE	Officer	Oct 15 '24	Proposed Sale	53.75	10,000	537,466		Oct 15 04:34 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Sale	54.00	10,000	539,961	676,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Sale	52.58	10,000	525,783	676,744	Oct 09 05:39 PM
HELEN TORLEY	Officer	Oct 09 '24	Proposed Sale	52.58	10,000	525,778		Oct 09 04:09 PM
HELEN TORLEY	Officer	Oct 08 '24	Proposed Sale	54.00	10,000	539,956		Oct 08 04:08 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Sale	58.21	10,000	582,100	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Sale	56.34	10,000	563,370	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Sale	56.10	10,000	560,970	676,744	Sep 26 06:06 PM
HELEN TORLEY	Officer	Sep 26 '24	Proposed Sale	56.10	10,000	560,970		Sep 26 04:05 PM
HELEN TORLEY	Officer	Sep 25 '24	Proposed Sale	56.34	10,000	563,368		Sep 25 04:00 PM
HELEN TORLEY	Officer	Sep 24 '24	Proposed Sale	58.21	10,000	582,101		Sep 24 04:05 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Sale	62.88	10,000	628,780	173,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Sale	62.03	10,000	620,316	173,756	Sep 18 06:49 PM
MICHAEL LABARRE	Officer	Sep 18 '24	Proposed Sale	62.03	10,000	620,311		Sep 18 04:01 PM
MICHAEL LABARRE	Officer	Sep 17 '24	Proposed Sale	62.88	10,000	628,777		Sep 17 04:03 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 12 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 12 '24	Sale	59.20	10,000	592,030	676,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '24	Sale	59.09	10,000	590,890	676,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '24	Sale	59.09	10,000	590,870	676,744	Sep 12 05:56 PM
HELEN TORLEY	Officer	Sep 12 '24	Proposed Sale	59.20	10,000	592,028		Sep 12 04:12 PM
HELEN TORLEY	Officer	Sep 11 '24	Proposed Sale	59.09	10,000	590,873		Sep 11 04:05 PM
HELEN TORLEY	Officer	Sep 10 '24	Proposed Sale	59.09	10,000	590,897		Sep 10 04:16 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 27 '24	Option Exercise	18.41	5,580	102,728	173,756	Aug 27 07:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Sale	61.75	10,000	617,470	168,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Sale	61.05	10,000	610,550	168,176	Aug 21 06:03 PM
MICHAEL LABARRE	Officer	Aug 21 '24	Proposed Sale	61.75	10,000	617,474		Aug 21 04:11 PM
MICHAEL LABARRE	Officer	Aug 20 '24	Proposed Sale	61.06	10,000	610,553		Aug 20 04:16 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Sale	57.95	10,000	579,490	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Sale	57.25	10,000	572,471	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Sale	56.25	10,000	562,490	676,744	Aug 15 04:59 PM
HELEN TORLEY	Officer	Aug 15 '24	Proposed Sale	57.95	10,000	579,488		Aug 15 04:31 PM
Posard Matthew L.	Director	Aug 14 '24	Sale	57.70	9,881	570,134	69,874	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 13 '24	Sale	56.19	10,000	561,930	79,755	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 12 '24	Sale	55.72	10,000	557,230	89,755	Aug 14 04:57 PM
HELEN TORLEY	Officer	Aug 14 '24	Proposed Sale	57.25	10,000	572,472		Aug 14 04:08 PM
HELEN TORLEY	Officer	Aug 13 '24	Proposed Sale	56.25	10,000	562,496		Aug 13 04:19 PM
Posard Matthew L.	affiliate	Aug 13 '24	Proposed Sale	54.15	30,000	1,624,500		Aug 07 04:41 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Option Exercise	15.19	10,000	151,854	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Option Exercise	8.11	10,000	81,100	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Sale	55.12	10,000	551,150	168,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Sale	54.89	10,000	548,873	168,176	Jul 24 05:48 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Option Exercise	22.50	5,000	112,500	19,488	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Sale	53.93	5,000	269,662	15,480	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Sale	52.04	10,000	520,400	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Sale	51.93	10,000	519,340	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	51.82	10,000	518,200	15,480	Jun 28 04:06 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Option Exercise	8.11	10,000	81,100	178,176	Jun 20 04:17 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Sale	49.43	10,000	494,260	168,176	Jun 20 04:17 PM
Posard Matthew L.	Director	Jun 12 '24	Sale	50.62	10,000	506,190	99,755	Jun 13 04:15 PM
Posard Matthew L.	Director	Jun 11 '24	Sale	50.01	10,000	500,110	109,755	Jun 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Sale	45.38	10,000	453,840	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Sale	45.16	10,000	451,640	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Sale	38.49	10,000	384,890	168,176	Apr 17 07:22 PM

Dollar change -1.10
Percentage change -0.49	%

BDX Becton Dickinson & Co daily Stock Chart

Peers: JNJ ABT DHR BAX TMO ISRG HOLX BSX ALGN XRAY

| Held by: VTI VOO SPY IVV VTV XLV VIG VHT IHI RSP

Index	S&P 500	P/E	37.18	EPS (ttm)	6.02	Insider Own	0.20%	Shs Outstand	287.14M	Perf Week	-0.13%
Market Cap	64.27B	Forward P/E	14.30	EPS next Y	15.65	Insider Trans	-2.10%	Shs Float	286.57M	Perf Month	-2.50%
Income	1.75B	PEG	4.15	EPS next Q	3.28	Inst Own	92.72%	Short Float	1.02%	Perf Quarter	1.73%
Sales	20.64B	P/S	3.11	EPS this Y	9.72%	Inst Trans	1.91%	Short Ratio	1.42	Perf Half Y	-5.65%
Book/sh	87.78	P/B	2.55	EPS next Y	8.53%	ROA	3.27%	Short Interest	2.94M	Perf Year	-6.70%
Cash/sh	2.89	P/C	77.43	EPS next 5Y	8.97%	ROE	6.92%	52W Range	218.75 - 251.99	Perf YTD	-1.34%
Dividend Est.	3.88 (1.73%)	P/FCF	21.89	EPS past 5Y	8.27%	ROI	4.10%	52W High	-11.18%	Beta	0.37
Dividend TTM	3.98 (1.78%)	Quick Ratio	0.63	Sales past 5Y	4.72%	Gross Margin	45.35%	52W Low	2.32%	ATR (14)	4.80
Dividend Ex-Date	Mar 10, 2025	Current Ratio	1.13	EPS Y/Y TTM	42.05%	Oper. Margin	14.13%	RSI (14)	41.42	Volatility	2.44% 1.89%
Employees	74000	Debt/Eq	0.74	Sales Y/Y TTM	5.89%	Profit Margin	8.47%	Recom	1.58	Target Price	271.00
Option/Short	Yes / Yes	LT Debt/Eq	0.69	EPS Q/Q	8.20%	Payout	64.86%	Rel Volume	1.01	Prev Close	224.92
Sales Surprise	1.33%	EPS Surprise	15.18%	Sales Q/Q	9.82%	Earnings	Feb 06 BMO	Avg Volume	2.07M	Price	223.82
SMA20	-1.17%	SMA50	-3.77%	SMA200	-3.88%	Trades		Volume	2,090,402	Change	-0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-24	Upgrade	Citigroup	Neutral → Buy	$255 → $275
May-30-24	Initiated	Goldman	Buy	$274
Jul-24-23	Upgrade	Raymond James	Mkt Perform → Outperform	$305
May-30-23	Resumed	Morgan Stanley	Overweight	$295
May-05-23	Upgrade	Piper Sandler	Neutral → Overweight	$260 → $290
Apr-12-23	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$304
Jan-03-23	Upgrade	BofA Securities	Neutral → Buy	$250 → $290
Dec-12-22	Upgrade	Citigroup	Sell → Neutral	$221 → $250
Jul-11-22	Downgrade	Citigroup	Neutral → Sell	$265 → $235
Jun-24-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$275
Mar-18-22	Resumed	Raymond James	Mkt Perform
Mar-02-22	Resumed	BofA Securities	Neutral	$290
Dec-08-21	Downgrade	Piper Sandler	Overweight → Neutral	$285 → $260
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral	$265
May-25-21	Initiated	Barclays	Equal Weight	$270
Dec-15-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$297
Dec-15-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$265
Jul-09-20	Upgrade	Barclays	Equal Weight → Overweight	$300
Jun-01-20	Resumed	Goldman	Buy	$278
Mar-05-20	Initiated	Citigroup	Neutral	$260

Show Previous Ratings

Mar-10-25 05:06AM	BD (NYSE:BDX): Strongest Q4 Results from the Surgical Equipment & Consumables - Diversified Group (StockStory)
Feb-28-25 09:45AM	Here's Why Becton Dickinson (BDX) is a Strong Growth Stock (Zacks)
04:07AM	3 Reasons to Sell BDX and 1 Stock to Buy Instead (StockStory)
Feb-27-25 09:40AM	Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term (Zacks)
Feb-20-25 05:23AM	BD business separation could allow competitors to rise in IVD test markets (Medical Device Network)
08:30AM	Loading…
Feb-18-25 08:30AM	Do Options Traders Know Something About BD (BDX) Stock We Don't? (Zacks)
Feb-13-25 04:15PM	BD to Present at Investor Healthcare Conferences (PR Newswire)
Feb-12-25 09:45AM	Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term (Zacks)
Feb-07-25 12:43PM	BD business split may prefigure life sciences division selloff (Medical Device Network)
09:30AM	Becton Dickinson price target raised to $269 from $265 at BofA (TipRanks)
02:07AM	Becton Dickinson & Co (BDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:08AM	Q1 2025 Becton Dickinson and Co Earnings Call (Thomson Reuters StreetEvents)
Feb-06-25 01:50PM	Becton Dickinson to Separate Biosciences and Diagnostic Solutions Business (GuruFocus.com) -7.28%
12:31PM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
10:24AM	Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business (Benzinga)
06:30PM	Loading…
Feb-05-25 06:30PM	Compared to Estimates, Becton Dickinson (BDX) Q1 Earnings: A Look at Key Metrics (Zacks)
05:55PM	Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates (Zacks)
05:02PM	Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business (The Wall Street Journal)
04:49PM	Becton Dickinson: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	BD Reports First Quarter Fiscal 2025 Financial Results (PR Newswire)
04:30PM	BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value (PR Newswire)
08:07AM	BD (BDX) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-03-25 09:16AM	Insights Into Becton Dickinson (BDX) Q1: Wall Street Projections for Key Metrics (Zacks)
09:09AM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
Jan-30-25 10:01AM	Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-28-25 04:15PM	BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25 (PR Newswire)
05:30AM	DEI Pay Incentives Come Under Pressure After Two-Year Surge (The Wall Street Journal)
Jan-24-25 12:27PM	Alphabet, Uber, Applied Materials, and 19 Other Picks From the Barrons Roundtable (Barrons.com)
Jan-23-25 07:15AM	BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development (PR Newswire)
Jan-22-25 11:07AM	Carilion to use BDs needle-free blood draw device (Medical Device Network)
06:50AM	Loading…
06:50AM	Carilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of Care (PR Newswire)
Jan-21-25 05:22PM	Masimo Taps Katie Szyman as Permanent CEO (The Wall Street Journal)
Jan-16-25 04:15PM	BD to Announce Financial Results for its First Quarter of Fiscal 2025 (PR Newswire)
Jan-15-25 08:56AM	Is Becton, Dickinson and Company (BDX) an Undervalued Stock? (Insider Monkey)
06:50AM	New Survey Reveals Nearly 3 in 4 Canadian Women Are Delaying Their OB/GYN Exams, Increasing Risks for Cervical Cancer (PR Newswire)
06:50AM	BD Boosts U.S. Manufacturing of Critical Medical Devices (PR Newswire)
Jan-14-25 02:06PM	3 in 4 women are skipping a routine appointment and putting themselves at higher risk for cancer (Fortune)
Jan-13-25 06:50AM	New ASCCP Guidelines Include More Precise Method of Cervical Cancer Screening (PR Newswire)
Jan-10-25 09:44AM	The Forgotten Four (GuruFocus.com)
06:50AM	BD Names Pamela Spikner as Chief Accounting Officer and Controller (PR Newswire)
Jan-09-25 09:45AM	Here's Why Becton Dickinson (BDX) is a Strong Growth Stock (Zacks)
06:50AM	New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer (PR Newswire)
Jan-07-25 04:15PM	BD To Host Virtual 2025 Annual Meeting of Shareholders (PR Newswire)
12:10PM	Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-03-25 09:40AM	Becton Dickinson (BDX) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Dec-20-24 09:45AM	Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term (Zacks)
Dec-18-24 09:40AM	Here's Why Becton Dickinson (BDX) is a Strong Value Stock (Zacks)
06:18AM	BD and Babson expand fingertip blood testing across US health systems (Medical Device Network)
Dec-17-24 09:50AM	Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term (Zacks)
06:50AM	BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations (PR Newswire)
Dec-16-24 05:52PM	Becton Dickinson to Pay $175 Million to Settle SEC Probe (Bloomberg)
04:46PM	Becton Dickinson settles charges over infusion pump risks, SEC says (Reuters)
04:32PM	BD Resolves Previously Disclosed SEC Investigation (PR Newswire)
08:08AM	Heres Why Matrix Asset Advisors Added Becton, Dickinson and Company (BDX) (Insider Monkey)
Dec-14-24 06:19AM	These 10 most-loved S&P 500 stocks could see as much as 50% upside in 2025 (MarketWatch)
12:10AM	Why Is Becton, Dickinson and Company (BDX) Among the Best Income Stocks to Buy According to Analysts? (Insider Monkey)
Dec-05-24 04:05PM	Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors (GlobeNewswire)
Dec-02-24 02:21PM	Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term (Zacks)
Nov-26-24 01:15PM	Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps (Benzinga)
Nov-20-24 02:15PM	First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities (PR Newswire)
Nov-19-24 04:15PM	BD to Present at the 7th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-12-24 01:02PM	First Eagle Investment Bolsters Stake in Becton Dickinson & Co in Q3 2024 (GuruFocus.com)
Nov-11-24 09:40AM	Are Investors Undervaluing Becton, Dickinson and Company (BDX) Right Now? (Zacks)
Nov-08-24 02:07AM	Becton Dickinson & Co (BDX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-07-24 11:56PM	Q4 2024 Becton Dickinson and Co Earnings Call (Thomson Reuters StreetEvents) -5.39%
01:18PM	Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And Pharma Market Dynamics To Impact 2025 Organic Revenue Growth (Benzinga)
12:45PM	Looking for a Growth Stock? 3 Reasons Why Becton Dickinson (BDX) is a Solid Choice (Zacks)
10:13AM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
09:30AM	Becton Dickinson (BDX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:45AM	Becton Dickinson (BDX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
06:52AM	Becton Dickinson: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results (PR Newswire)
06:25AM	BD Board Increases Dividend for 53rd Consecutive Year (PR Newswire)
Nov-04-24 09:16AM	Insights Into Becton Dickinson (BDX) Q4: Wall Street Projections for Key Metrics (Zacks)
Nov-03-24 01:37PM	Becton, Dickinson and Company (BDX): Expanding Innovations in Medical Technology (Insider Monkey)
Oct-31-24 10:01AM	Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-30-24 09:40AM	Here's Why Becton Dickinson (BDX) is a Strong Value Stock (Zacks)
06:50AM	BD Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations (PR Newswire)
06:05AM	BDs Onclarity HPV Assay receives Health Canada approval (Medical Device Network)
Oct-29-24 09:45AM	Here's Why Becton Dickinson (BDX) is a Strong Growth Stock (Zacks)
06:50AM	Women in Canada Can Now Collect Their Own Sample at Home for Cervical Cancer Screening (PR Newswire)
Oct-25-24 06:53AM	BD Named Among the 100 Best Corporate Citizens of 2024 (PR Newswire)
Oct-22-24 12:45PM	3 Reasons Why Becton Dickinson (BDX) Is a Great Growth Stock (Zacks)
Oct-15-24 05:07AM	BD launches automated, robotics-compatible reagent kits (Medical Device Network)
Oct-14-24 09:40AM	Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term (Zacks)
06:45AM	BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research (PR Newswire)
Oct-11-24 12:10PM	Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:45AM	Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term (Zacks)
Oct-10-24 07:21PM	Is Becton, Dickinson and Company (NYSE:BDX) The Most Popular Stock Among Mutual Funds According To Goldman Sachs? (Insider Monkey)
04:15PM	BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results (PR Newswire)
Oct-07-24 09:50AM	Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock (Zacks)
Oct-03-24 05:05PM	Becton Dickinson in pact to to resolve vast majority of hernia litigation (TipRanks)
Oct-02-24 05:00PM	BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation (PR Newswire)
08:40AM	Becton Dickinson target raised, added to Tactical Outperform list at Evercore (TipRanks)
Sep-26-24 06:50AM	New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion (PR Newswire)
Sep-25-24 04:05PM	PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples (GlobeNewswire)
Sep-18-24 06:50AM	BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics (PR Newswire)
Sep-10-24 09:40AM	Here's Why Becton Dickinson (BDX) is a Strong Value Stock (Zacks)
Sep-09-24 09:45AM	Here's Why Becton Dickinson (BDX) is a Strong Growth Stock (Zacks)
Sep-04-24 05:32AM	BD completes acquisition of Edwards Lifesciences Critical Care product group (Medical Device Network)

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RICHARD BYRD	Officer	Mar 12 '25	Proposed Sale	224.92	1,940	436,345		Mar 12 04:22 PM
SCOTT BERTRAM L	Director	Feb 12 '25	Sale	227.99	700	159,593	36,033	Feb 12 04:44 PM
BERTRAM SCOTT	Director	Feb 12 '25	Proposed Sale	227.99	700	159,593		Feb 12 04:12 PM
Henderson Jeffrey William	Director	Feb 10 '25	Buy	233.62	1,500	350,430	8,015	Feb 10 05:03 PM
Shan David	EVP and Chief ISC Officer	Jan 21 '25	Sale	240.00	500	120,000	5,741	Jan 22 09:19 AM
Neal Shana Carol	EVP and Chief People Officer	Jan 21 '25	Sale	240.00	787	188,880	15,414	Jan 22 09:18 AM
SHANA NEAL	Officer	Jan 21 '25	Proposed Sale	237.38	787	186,818		Jan 21 04:21 PM
DAVID SHAN	Officer	Jan 21 '25	Proposed Sale	237.38	500	118,690		Jan 21 01:47 PM
Garrison Michael David	EVP & President, Medical	Jan 17 '25	Sale	236.51	597	141,196	5,544	Jan 21 08:21 AM
MICHAEL GARRISON	Officer	Jan 17 '25	Proposed Sale	236.30	597	141,071		Jan 17 04:20 PM
Neal Shana Carol	EVP and Chief People Officer	Nov 21 '24	Option Exercise	0.00	111	0	17,021	Jan 10 07:11 AM
Neal Shana Carol	EVP and Chief People Officer	Jan 07 '25	Sale	235.00	788	185,180	16,201	Jan 10 07:11 AM
SHANA NEAL	Officer	Jan 07 '25	Proposed Sale	230.70	788	181,792		Jan 07 04:19 PM
Garrison Michael David	EVP & President, Medical	Dec 19 '24	Sale	223.33	2,838	633,811	6,141	Dec 20 10:18 AM
MICHAEL GARRISON	Officer	Dec 19 '24	Proposed Sale	224.09	2,838	635,967		Dec 19 04:20 PM
Goette Roland	EVP and President, EMEA	Dec 06 '24	Option Exercise	157.30	13,334	2,097,403	28,828	Dec 10 08:23 PM
Goette Roland	EVP and President, EMEA	Dec 06 '24	Sale	221.01	4,483	990,788	24,345	Dec 10 08:23 PM
Goette Roland	EVP and President, EMEA	Dec 09 '24	Sale	219.03	638	139,741	14,217	Dec 10 08:23 PM
Neal Shana Carol	EVP and Chief People Officer	Dec 06 '24	Sale	220.49	1,000	220,490	16,989	Dec 10 08:17 PM
ROLAND GOETTE	Officer	Dec 09 '24	Proposed Sale	220.02	638	140,373		Dec 09 04:47 PM
Shan David	EVP and Chief ISC Officer	Dec 05 '24	Sale	220.25	1,500	330,375	6,285	Dec 06 04:55 PM
ROLAND GOETTE	Officer	Dec 06 '24	Proposed Sale	222.24	4,483	996,302		Dec 06 04:31 PM
SHANA NEAL	Officer	Dec 06 '24	Proposed Sale	222.24	1,000	222,240		Dec 06 04:31 PM
DAVID SHAN	Officer	Dec 05 '24	Proposed Sale	221.43	1,500	332,145		Dec 05 04:42 PM
BURZIK CATHERINE M	Director	Sep 16 '24	Proposed Sale	235.78	400	94,312		Sep 16 11:52 AM
Goette Roland	EVP and President EMEA	Aug 14 '24	Option Exercise	132.54	5,295	701,799	16,603	Aug 15 01:47 PM
Spoerel Thomas J	SVP,Controller&Chief Acct Off	Jun 10 '24	Sale	239.31	300	71,793	1,976	Jun 11 01:45 PM
Goette Roland	EVP and President EMEA	May 15 '24	Sale	236.73	3,300	781,224	11,308	May 16 07:54 PM
Goette Roland	EVP and President EMEA	May 13 '24	Sale	236.70	3,300	781,121	14,608	May 15 02:44 PM
Garrison Michael David	EVP & President Medical	Apr 30 '24	Sale	232.81	1,715	399,269	5,381	May 01 12:59 PM
Spoerel Thomas J	SVP,Controller&Chief Acct Off	Mar 14 '24	Sale	238.29	282	67,198	2,276	Mar 15 02:19 PM

Open in Screener

FGEN

FibroGen Inc

Mar 12 • 04:00PM ET

0.4603

Dollar change +0.0472
Percentage change 11.43	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN REGN ALNY IONS NBIX MDGL EXEL ARGX PRTA

| Held by: VTI VXF VHT IWC FESM BTEC

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	6.62%	Shs Outstand	100.77M	Perf Week	16.83%
Market Cap	46.39M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	94.10M	Perf Month	-7.63%
Income	-121.79M	PEG	-	EPS next Q	-0.14	Inst Own	36.16%	Short Float	5.63%	Perf Quarter	34.55%
Sales	180.01M	P/S	0.26	EPS this Y	72.60%	Inst Trans	-24.72%	Short Ratio	1.48	Perf Half Y	16.59%
Book/sh	-2.42	P/B	-	EPS next Y	43.12%	ROA	-33.61%	Short Interest	5.30M	Perf Year	-74.43%
Cash/sh	1.30	P/C	0.35	EPS next 5Y	49.32%	ROE	-	52W Range	0.18 - 2.80	Perf YTD	-13.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.23%	ROI	-	52W High	-83.56%	Beta	0.74
Dividend TTM	-	Quick Ratio	1.16	Sales past 5Y	-8.26%	Gross Margin	76.87%	52W Low	155.72%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	1.28	EPS Y/Y TTM	59.81%	Oper. Margin	-52.44%	RSI (14)	49.54	Volatility	12.24% 14.33%
Employees	486	Debt/Eq	-	Sales Y/Y TTM	16.15%	Profit Margin	-67.66%	Recom	2.00	Target Price	10.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	73.75%	Payout	-	Rel Volume	0.50	Prev Close	0.41
Sales Surprise	32.98%	EPS Surprise	44.50%	Sales Q/Q	15.45%	Earnings	Mar 17 AMC	Avg Volume	3.58M	Price	0.46
SMA20	-4.69%	SMA50	-10.60%	SMA200	-20.07%	Trades		Volume	1,794,853	Change	11.43%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform	$4 → $2
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-02-23	Upgrade	Stifel	Hold → Buy	$23 → $32
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$35
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy	$18 → $27
Sep-22-21	Downgrade	Goldman	Neutral → Sell	$16 → $11
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	Stifel	Buy → Hold	$55 → $29
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral	$29
Apr-07-21	Downgrade	Mizuho	Buy → Neutral	$72 → $29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy	$47
Mar-02-21	Downgrade	Jefferies	Buy → Hold	$75 → $45
Feb-01-21	Initiated	H.C. Wainwright	Buy	$58
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy	$71

Show Previous Ratings

Mar-03-25 04:45PM	FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.78% -5.33%
Feb-20-25 04:02PM	FibroGen sells China unit to AstraZeneca for $160m (Pharmaceutical Technology) +37.44% -8.61%
06:40AM	AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal (Reuters)
06:30AM	FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million (GlobeNewswire)
05:55AM	AstraZeneca deepens China presence with FibroGen deal (BioPharma Dive)
08:05AM	Loading…
Dec-16-24 08:05AM	FibroGen Appoints David DeLucia as Chief Financial Officer (GlobeNewswire)
Nov-13-24 10:22AM	Q3 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -14.07%
02:21AM	FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions (GuruFocus.com)
Nov-12-24 06:10PM	FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +14.18%
05:06PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 04:05PM	FibroGen to Report Third Quarter 2024 Financial Results (GlobeNewswire) -5.65%
Oct-09-24 05:09PM	FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts (GuruFocus.com)
Sep-16-24 01:32AM	Duchenne muscular dystrophy: major trials and events to watch in 2023 (Clinical Trials Arena)
Sep-03-24 04:05PM	FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -9.19% +20.36%
06:15PM	Loading…
Aug-06-24 06:15PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:10PM	FibroGen: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 11:54AM	FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials (Pharmaceutical Technology) -47.56%
07:33AM	Vertexs pain drug gets speedy FDA review; Keytruda hits a sales milestone (BioPharma Dive)
Jul-30-24 04:07PM	FibroGen to Report Second Quarter 2024 Financial Results (GlobeNewswire) -8.04%
04:05PM	FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update (GlobeNewswire)
Jun-18-24 08:00AM	FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024 (GlobeNewswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-03-24 04:05PM	FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO in Upcoming Clinical Trials (GlobeNewswire)
04:02PM	FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors (GlobeNewswire)
09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
07:00AM	FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
05:05PM	Loading…
May-23-24 05:05PM	FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-07-24 10:15AM	FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +18.10%
08:57AM	Q1 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:00AM	FibroGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:14AM	FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-24 08:58PM	FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:25PM	FibroGen: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 07:00AM	FibroGen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:02PM	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.01%
Apr-03-24 09:32AM	Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak (FierceBiotech.com) -31.94%
Apr-02-24 05:46PM	FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -8.47%
Mar-26-24 07:00AM	FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.58%
Mar-20-24 03:45PM	3 Nightmare Nasdaq Stocks Not Worth Holding Another Day (InvestorPlace)
Mar-11-24 07:00AM	FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer (GlobeNewswire)
Feb-29-24 08:09AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -13.85%
Feb-27-24 09:59AM	Q4 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) +14.59%
Feb-26-24 05:50PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 (GuruFocus.com)
04:34PM	UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:15PM	FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:06PM	FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea (GlobeNewswire)
Feb-20-24 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -17.81%
Feb-05-24 07:00AM	FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 (GlobeNewswire) +8.87%
Jan-25-24 07:00AM	FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer (GlobeNewswire) +13.37%
Dec-09-23 05:02PM	FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-07-23 11:01AM	FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:01AM	Q3 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:33PM	FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue (GuruFocus.com) -13.62%
05:30PM	FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:10PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	FibroGen Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 07:00AM	FibroGen to Report Third Quarter 2023 Financial Results (GlobeNewswire) -7.77%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks) -24.23%
Aug-29-23 06:00PM	FibroGen's drug misses mark on yet another clinical trial (American City Business Journals)
04:15PM	FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-16-23 09:35AM	Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Aug-09-23 09:14AM	Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation? (Simply Wall St.)
Aug-08-23 10:08AM	Q2 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -18.64%
08:59AM	FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:30PM	FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -7.33%
05:40PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	FibroGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:00AM	FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives (American City Business Journals) +7.29%
Jul-25-23 10:49AM	FibroGen CEO resigns after back-to-back drug study failures, job cuts (American City Business Journals) -5.74%
07:00AM	FibroGen Announces Leadership Transition (GlobeNewswire)
Jul-24-23 07:00AM	FibroGen to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -5.41%
Jul-19-23 10:50AM	Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs (American City Business Journals) -7.03%
Jul-14-23 09:55AM	FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jul-11-23 09:35AM	Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Jul-01-23 08:46AM	Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? (Motley Fool)
Jun-27-23 12:45PM	FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study (Zacks) -7.38%
Jun-26-23 04:04PM	FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug (Investor's Business Daily) -83.12%
11:34AM	FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains (Simply Wall St.)
07:22AM	UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease (Reuters)
07:11AM	FibroGen's lung disease treatment fails in late-stage trial (Reuters)
07:04AM	FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-08-23 01:03PM	FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8% (Zacks)
Jun-07-23 04:03PM	FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost (Investor's Business Daily) -8.44%
11:47AM	FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal (Benzinga)
07:02AM	FibroGen's neuromuscular disease drug fails to meet main goal in late-stage study (Reuters)
06:55AM	FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-06-23 04:01PM	FibroGen to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
02:06PM	FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 (Investor's Business Daily)

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adib Deyaa	Chief Medical Officer	Jun 12 '24	Buy	1.17	22,123	25,884	82,123	Jun 13 04:30 PM

HALO

Halozyme Therapeutics Inc

BDX

Becton Dickinson & Co

FGEN

FibroGen Inc

Upgrade your FINVIZ experience